Lake Street analyst Brooks O’Neil initiated coverage of LifeVantage (LFVN) with a Buy rating and $26 price target The company’s products activate physical wellness by using science-based formulas that unlock genes to restore optimal cellular function, says the analyst, who expects rapid growth of the MindBody GLP-1 System that targets a demographic looking for a natural approach to the weight loss benefits of GLP-1s to drive the company’s results this quarter and going forward. While “only” modeling 2% revenue growth in FY25, the firm expects EPS growth of 196% and think shares are “attractively valued,” the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LFVN:
- LifeVantage returns TrueScience Hydrating Lip Oil to U.S. Market
- LifeVantage Reports Q1 Fiscal 2025 Financial Results
- LifeVantage announces results from MindBody GLP-1 System trial
- LifeVantage reports Q1 EPS 15c, one-estimate 15c
- LifeVantage sees QFY25 EPS 70c-80c, consensus 72c
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
